Promotional material

Vaccine update: issue 366, December 2025

Published 23 December 2025

As we prepare to say goodbye to 2025, the Immunisation programmes division is reflecting on our most ambitious year of change. It included the implementation of a challenging set of significant vaccination schedule improvements and the addition of 2 new vaccination programmes that now offer more protection from infectious disease and sequelae.

It is important to recognise the powerful role the public has in supporting the national vaccination programmes by coming forward for vaccination. The levels of trust they have in health professionals remains high and is very precious. Practice nurses, health visitors, midwives, school aged immunisers and all our other colleagues who contribute to the immunisation pathway are so valued, and your expertise, knowledge and care is evident in all best practice. Thank you for each and every vaccine given – each one is a step further towards building herd immunity in our community to protect those too young or immunocompromised who are not able to have vaccines themselves to protect them from infectious disease.

It was 5 years ago on the 8 December 2020 when Margaret Keenan, now 91, originally from Ireland but a resident of Coventry for over 60 years, was given a Pfizer/BioNTech vaccination.

Mrs Keenan, known as Maggie, was given her booster vaccine by Matron May Parsons.

The 91-year-old said:

I cannot tell you how pleased I am really […] the best Christmas present I could have is being in good health.

Since then millions of COVID-19 vaccinations have been given by health care professionals like Matron May Parsons. This year, as in 2024, we had a spring and autumn programme to protect those most vulnerable. As the risk of infection with COVID-19 reduces for some groups and there are greater levels of immunity in the population, the eligible groups have become much smaller due in part to the great success of the programme. Despite these annual changes, the teams delivering these vaccines continue to implement the COVID-19 and seasonal influenza programmes extremely effectively and with good uptake. We extend our deepest thanks to the efforts of provider colleagues in primary care and pharmacy who continue to make vaccination accessible and available across the country

As more people live longer healthier lives protected by vaccination, quality of life remains better for longer.

• the roll out of the RSV vaccination for pregnant women and older adults on 1 September 2024 continued at pace during this year with 2,427,908 vaccinations have been given in England ^{[footnote 1]}
• this year also saw the extension of the Shingles vaccination programme from 1 September 2025, to all severely immunosuppressed individuals aged 18 years and over ^{[footnote 2]}
• the seasonal influenza programme is protecting more people than ever with vaccine uptake higher for pregnant women, those aged 2 and those aged 3 and comparable for those aged 65 years and over and those aged under 65 years in clinical risk groups ^{[footnote 3]}

All change!

2025 has been one of the most ambitious years for change in the national Immunisation programme in 30 years. We have had 2 phases to the changes to the childhood programme and you can read all about the MMRV programme for infants aged 12 and 18 months in the Vaccine update special 367.

You can also read about the first phase of these changes in the June Special, Vaccine Update: 359. MMR will remain available as part of the routine schedule for those not eligible for MMRV and to order for vaccinating older cohorts and adults who have missed MMR vaccination.

18 month appointment from 1 January 2026 – just when infants need it most

Phase 1 childhood changes included the new offer of an 18 month appointment with the addition of a hexavalent 6-in-1 vaccine at 18 months and its implications for children on the selective hepB immunisation programme. By offering a complete course of 4 (or in the case of those on the selective hepB programme, 6) we are protecting children from 6 diseases which can have long term impacts on their health and quality of life.

In England, 12-month coverage of the ‘6-in-1’ increased by 0.1 percentage points to 91.3%. This is a small but important improvement that we hope to improve in 2026

4CMenB for GBMSM launched last summer

In August 2025, the UK became the first country in the world to offer the 4CMenB vaccine for protection against gonorrhoea in high risk populations. 4CMenB is licensed for protection against invasive meningococcal disease (IMD) caused by serogroup B (MenB) Neisseria meningitidis and is currently offered to infants as part of routine national immunisation programme. Because Neisseria meningitidis (the meningococcus) and Neisseria gonorrheoeae (the gonococcus) are  genetically closely related, 4CMenB also offers some protection (around 20 to 40%) against gonorrhoea. To combat the rising incidence of gonorrhoea and increasing rates of antibiotic resistance, the UK JCVI advised the offer of 4CMenB to populations at high risk of gonorrhoea through sexual health services. The programme primarily targets gay, bisexual and other men who have sex with men (GBMSM) who are at increased risk of gonorrhoea, as defined by the number of recent sexual partners and recent history of bacterial sexually transmitted infections (STI).

Visit the Meningococcal B (MenB) vaccination programme collection for more information on the Meningococcal B (MenB) vaccination for Gonorrhoea.

Launch of website for families and professionals about the HPV vaccine

A website to help teenagers and parents find out about the human papillomavirus (HPV) vaccine in schools is now available. The HPV Inform website will contribute to overcoming HPV vaccine misinformation and empowering families with access to information they need to make decisions which can help protect their teenage children’s health.

HPV is a common infection that is spread by skin-to-skin contact, including sexual contact.  The HPV vaccine is usually offered to teenagers at school as part of the NHS vaccination programme.  Research has shown that in England the vaccination programme for 12-13 year olds has almost  eliminated cervical cancer among young women born since 1995 and is good value for money for the NHS. However, to gain these benefits uptake of the vaccine must be high.

The vaccine helps prevent infection with the strains of HPV that are responsible for causing some cancers in both women and men. These include cancers affecting the cervix and some cancers affecting the vulva, vagina, penis, anus, mouth and throat.  The HPV vaccine also provides protection against genital warts.

The HPV Inform website, co-created by researchers from the University of Bristol alongside families and key stakeholders, has information and helpful resources for young people, parents/carers and professionals to find out:

• what HPV is and the different illnesses it can cause
• how the HPV vaccine protects young people, and it’s safety and side effects
• how and where to get the vaccine
• tips to help young people getting the vaccine at school

The website includes resources created by the project team as part of the EDUCATE and COMMUNICATE research studies. As well as resources that young people and parents can access directly, there are also lesson plans which could be used by school staff or immunisation teams to provide information to young people in school, for example in PHSE lessons, tutor time or assembly. 

Dr Harri Fisher, Research Fellow in Bristol Medical School: Population Health Sciences (PHS) and National Institute for Health and Care Research (NIHR) Health Protection Research Unit [HPRU] in Evaluation and Behavioural Science at the University of Bristol, said:

We are really excited to be able to launch this website so that families have easy access to information to help support their decisions about the HPV vaccine.

Further information can be found on the NIHR HPRU EBS Project webpage.

If you are a school aged vaccination provider delivering the HPV vaccination in schools in London, and would be interested in featuring in Vaccine Update for our how we did it feature, please get in touch with Immunisation.website@ukhsa.gov.uk

Help us track Flu in the UK

Every winter, coughs, colds and flu sweep across the country. We know this keeps you busy during this time. Many people follow advice and manage their illnesses at home but how many people are affected like this is often an unclear picture.

FluSurvey is here to change that. It’s a national system run by UKHSA which tracks flu-like symptoms and other respiratory illnesses by collecting weekly updates from people at home. All you need to do is register once, then each week during flu season tell us how you’re feeling. It takes less than a minute.

We’ll also keep you posted with the latest data on what’s happening with Flu, RSV and COVID-19.

The more people who take part, the clearer the picture becomes. Sign up today!

How we did it: Learning about the lifelong protection from routine vaccination with children in Knowsley

In Knowsley, we’ve seen how quickly illnesses like measles can spread when not enough children are vaccinated, and how uptake can be lower in some communities.

That’s why the Explore Community Innovation Team decided to do something different. Instead of only speaking to parents about vaccines, they asked:

What if we helped children learn about immunisation for themselves, and let them lead the conversation?

Listening first

The team worked with Knowsley’s vaccines and immunisation service to look at local data and identify schools and nurseries with the lowest uptake. But numbers only told part of the story.

So, they visited classrooms, talked with children, teachers and nursery staff, and listened carefully to their views. They asked simple questions about what people knew, and didn’t know, about topics like healthy eating and immunisation. The answers helped shape the next stage of the project.

Why children’s voices count

When we talk about vaccines, most of the focus is on parents. But children are naturally curious. They ask questions, they share what they’ve learnt, and they’re often the ones sparking conversations at home.

Teachers also explained that while they feel confident teaching topics like healthy eating, they are less sure about how to approach immunisation in the classroom. That’s where the team realised that they could make a real difference.

Together with teachers and health partners, the Explore Community Innovation team created the Hero Academy, a fun, creative workbook that takes children on a learning adventure through different aspects of health, from exercise and healthy eating to mental wellbeing and immunisation.

To make it even more engaging, schools were offered drama workshops. Pupils could choose which topic to bring to life on stage and most chose immunisation as their main theme. Their performances not only showed off their creativity but also gave them the chance to share what they’d learnt with parents and carers.

Looking Ahead

The project doesn’t stop here. More resources are being developed so teachers can continue running these activities in future years. And the work is expanding; the Explore Community Innovation Team is now partnering with 3 Knowsley Primary Care Networks to bring the programme to 10 more schools with the lowest childhood immunisation uptake.

Working Together for Children

This project is a partnership between Explore Partnership CIC, Knowsley Public Health, NHS ICB Knowsley, Merseycare, Knowsley MBC, Central and South PCN Knowsley, and creative organisation Silly Fish Learning. It is supported by the Liverpool School of Tropical Medicine as part of the ReCITE project, funded by the Arts and Humanities Research Council (AHRC) and UK Research and Innovation (UKRI).

For more information, please contact: ReCITEproject@lstmed.ac.uk

The Immunisation Publications Stand wishes everyone a happy festive season

It has been another fantastic year on the road with the immunisation publications stand. We have been at over 25 wonderful events promoting vaccination and our materials to support immunisers and the public in engaging this important aspect of public health. Thank you to everyone who has dropped by, asked us questions, signed up for Vaccine Update and taken away materials to use in their local practice. Whether it was stickers or leaflets or information on the new Find Public Health Resources website launched this year, we are grateful for every interaction we have while we are on the road. Please continue to look out for our stand at public health events, drop by and collect any resources that can be of use, chat to our team and learn more. While we are on our festive break, please continue to use Find Public Health Resources and do get in touch with us at publichealthresources@ukhsa.gov.uk if you would like to see our stand at an event near you!

Find Public Health Resources winter holiday hours

Ordering via phone will not be available from 2pm on 24 December until 9am on 3 January. Any urgent queries relating to the vaccination programme publications deliveries can be sent via email to publichealthresources@ukhsa.gov.uk.

You can still place orders on the website as normal by visiting Find Public Health Resources.

Vaccine supply

Routine vaccination programme

Attention all ImmForm customers: Christmas and New Year holiday deliveries

Due to Christmas and New Year holidays, there will be no deliveries or order processing by Movianto on Thursday 25 and Friday 26 December 2025, nor on Thursday 1 January 2026. See the table below for your revised order and delivery days, and the additional information for offshore customers.

All customers should prepare for this break in deliveries and order accordingly. Ensure you have enough room in your fridge for any additional vaccine that you order in advance of this holiday period, bearing in mind the recommendation that only 2 to 4 weeks of vaccine stock should be held locally.

Please be advised that no emergency or out of schedule deliveries can be arranged for ImmForm customers who fail to place their orders by the cut-off date and time.

Delivery date	Order cut-off date	Order cut-off time	Notes / holidays
Wednesday 24 December 2025	Monday 22 December 2025	11:55 am
Thursday 25 December 2025			No deliveries or order processing
Friday 26 December 2025			No deliveries or order processing
Monday 29 December 2025	Tuesday 23 December 2025	11:55 am
Tuesday 30 December 2025	Wednesday 24 December 2025	11:55 am
Wednesday 31 December 2025	Monday 29 December 2025	11:55 am
Thursday 1 January 2026			No deliveries or order processing
Friday 2 January 2026	Tuesday 30 December 2025	11:55 am	No deliveries to Scotland customers
Monday 5 January 2026	Wednesday 31 December 2025	11:55 am
Tuesday 6 January 2026	Friday 2 January 2026	11:55 am
Wednesday 7 January 2026	Monday 5 January 2026	11:55 am
Thursday 8 January 2026	Tuesday 6 January 2026	11:55 am
Friday 9 January 2026	Wednesday 7 January 2026	11:55 am

Offshore customers:

• Isle of Wight and Isle of Man: See the table above for your revised order and delivery days
• Jersey, Guernsey, Shetland, Stornoway and Orkney: No deliveries will be made after Tuesday 23 December 2025 until Wednesday 7 January 2026.

See the table above for our revised order and delivery days.

COVID-19 and mpox vaccine offshore customers:

• Guernsey, Jersey, Isle of Man and Scottish islands: The final orders before Christmas will be handed to the courier on Monday 22 December 2025 for the final mile delivery on Tuesday 23 December 2025. The first delivery after Christmas will be handed to the courier on Monday 29 December 2025 for the final mile delivery on Tuesday 30 December 2025

Change of vaccine for the routine adult pneumococcal vaccination programme and individuals at increased clinical risk

During early 2026, the vaccine used for the routine pneumococcal vaccination programme for adults, for those aged 2 years and above in clinical risk groups for pneumococcal disease, and for children aged less than 2 years of age with asplenia, splenic dysfunction, complement disorder or severe immunosuppression will change from Pneumovax® 23 (PPV23) to Prevenar 20® (PCV20).

The vaccine for the routine childhood pneumococcal vaccination programme (Prevenar 13® / PCV13) remains unchanged and should continue to be offered to all children at 16 weeks and one year of age.

Details about the pneumococcal vaccination programme is published in the Green Book - Pneumococcal: the green book, chapter 25.

Details about the change in vaccine can be found at: Change of vaccine for the routine adult pneumococcal vaccination programme and individuals at increased clinical risk

Please continue to order and administer Pneumovax® 23 (PPV23) until ImmForm and your local stockholdings deplete.

Prevenar 20® vaccine will be available to order via ImmForm from early 2026. High-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity.

Prevenar 20® vaccine ordered via ImmForm will be supplied as a 10-dose pack containing 10 pre-filled syringes and 10 patient information leaflets (PILs). Unlike with Pneumovax® 23, the pack does not contain any needles for administration. Guidance on the choice of needle size can be found in: Immunisation procedures: the green book, chapter 4. Needles and syringes should be obtained locally.

Further details about Prevenar 20® vaccine can be found at: [Prevenar 20 suspension for injection in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)

13461](https://www.medicines.org.uk/emc/product/13461/smpc).

To help with planning storage requirements:

• the dimensions of each 10-dose pack of Prevenar 20® vaccine are 99 x 62 x 123 mm (H x W x D).

Please add Prevenar 20® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 to 4 weeks’ worth of stock. Further guidance can be found at: Storage, distribution and disposal of vaccines: the green book, chapter 3. 

Contact the helpdesk@immform.org.uk for ordering queries

Introduction of a combined measles, mumps, rubella and varicella (MMRV) vaccine

From 1 January 2026, the NHS routine childhood vaccination programme will include a combined measles, mumps, rubella and varicella (MMRV) vaccine. See more details about the introduction of MMRV vaccination.

From 1 January 2026, the current MMR vaccines (M‑M‑RvaxPro® and Priorix®) will continue to be available to order via ImmForm for administration outside of the routine childhood programme, for example, for vaccination of older individuals, that is, those born on or before 31 December 2019, who have not received 2 doses of MMR and are not eligible for MMRV.

ProQuad® and Priorix-Tetra® will be the vaccines used for the MMRV programme. ProQuad® and Priorix-Tetra® vaccines will be available for ImmForm customers in England and Wales to order from Monday 1 December 2025. ProQuad® vaccine should be ordered for all MMRV vaccinations, unless a patient requires a porcine gelatine-free MMRV vaccine. ImmForm customers in England and Wales may order ProQuad® vaccine with only a high-level ordering control in place to reduce the risk of ordering errors only. This is not intended to restrict activity.

In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix-Tetra® doses per account per week. Please note there are 10 Priorix-Tetra® doses in each vaccine pack ordered via ImmForm. Scottish customers should refer to local ordering guidance.

ProQuad® vaccine ordered via ImmForm will be supplied as a single-dose pack, containing one pre-filled syringe, one vial of solvent for reconstitution, one patient information leaflet (PIL), and 2 unattached non-safety needles. One needle should be used for reconstitution and a separate, new needle for injection.

See more details about ProQuad® vaccine

Priorix-Tetra® vaccine ordered via ImmForm will be supplied as a 10-dose pack, containing 10 single-dose vials (10 x 0.5 ml) of vaccine, 10 single-dose vials of diluent and one patient information leaflet (PIL). Each 10-dose pack of Priorix-Tetra® vaccine ordered via ImmForm will also be supplied with a pad of 10 additional PILs. Priorix-Tetra® vaccine supplied via ImmForm does not contain needles for administration.

Further details about Priorix-Tetra® vaccine can be found here: Priorix Tetra

Further guidance on the choice of needle size can be found in Immunisation procedures: the green book, chapter 4. Needles should be obtained locally.

To help with planning storage requirements:

• the dimensions of each single-dose pack of ProQuad® vaccine are 150 x 47 x 28 mm (H x W x D) - the dimensions of each larger 10-dose pack of Priorix-Tetra® vaccine are 142 x 178 x 29 mm (H x W x D)

To minimise wastage due to fridge failures, please order no more than 2 to 4 weeks’ worth of stock. Further guidance can be found in the Green Book: Chapter 3.

Contact the helpdesk@immform.org.uk for ordering queries

Availability of Menitorix vaccine

Since 1 July 2025, Menitorix® vaccine is no longer offered to children who turn one year old.

ImmForm customers in England and Scotland remain able to order Menitorix® vaccine for those children previously eligible for it. After ImmForm and your local stockholdings of Menitorix® vaccine deplete, those previously eligible children should be offered a dose of DTaP/Hib/IPV/HepB vaccine, also available via ImmForm.

Menitorix® vaccine is no longer offered to any children in Wales. Health Boards should ensure that any remaining stock of Menitorix® vaccine is safely disposed of in accordance with local waste disposal procedures. All such wastage should also be recorded on ImmForm.

Details of the changes to the routine immunisation schedule are available here - Complete routine immunisation schedule.

Vaccines for the 2025 to 2026 children’s flu programme supplied by UKHSA

All flu vaccines for the 2025/26 children’s flu programme are available to order by general practice and school-age providers in England via ImmForm.

Community pharmacies who are delivering flu vaccinations to 2 and 3 year olds can access Fluenz® (LAIV) via the Federated Data Platform (FDP) managed by NHS England. Vaccines for this service will not be available to order through ImmForm. UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Expiry dates for all batches of Fluenz® issued for the 2025 to 2026 children’s flu programme

Batch numbers and associated expiry dates of all batches of Fluenz® that either have or will be issued this season are set out in the table below. Please ensure that the expiry date is always checked before use, and that expired stock is disposed of in line with local policies. Any disposed stock should be recorded through the ImmForm stock incident page.

Batch number	Expiry date	Batch number	Expiry date
YF2962	9 December 2025	YK2680B	5 January 2026
YF2962B	9 December 2025	YK2763	6 January 2026
YF2965	10 December 2025	YK2682	12 January 2026
YF2965B	10 December 2025	YK2682B	12 January 2026
YF2963	15 December 2025	YK2998	19 January 2026
YF3265	15 December 2025	YL2477	2 February 2026
YF3265B	15 December 2025	YL2477B	2 February 2026
YF2964	16 December 2025	YM2013B	9 February 2026
YF3276	16 December 2025	YL2672	16 February 2026
YH2667	22 December 2025	YL2672B	16 February 2026
YH2667B	22 December 2025	YM2014	23 February 2026
YF3414	29 December 2025	YL2671	2 March 2026
YF3414B	29 December 2025	YL2671B	30 March 2026
YK2680	5 January 2026

Vaccines and availability

The 2 vaccines that will be available, preliminary indicative ordering dates and the groups that these vaccines should be ordered for are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	All children from 2 years of age to school year 11
Children in clinical risk groups aged from 2 up to their 18th birthday [note 1]
Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc)	Seqirus	Children in clinical risk groups aged from 6 months up to their 2nd birthday
All other eligible [note 2] children aged from 2 up to their 18th birthday for whom LAIV is unsuitable

Note 1: Unless LAIV clinically contraindicated or otherwise unsuitable.

Note 2: Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to less than 18 years.

LAIV ordering information for general practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls will work by allocating an amount of LAIV based on the umber of registered eligible patients and will be tailored to each practice.

• each GP practice will initially be allocated sufficient LAIV to vaccinate at least 45% of its eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to less than 18 years) when ordering commences
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period – requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off
• out-of-schedule deliveries will be by exception only

This vaccine has a short shelf life. Try to hold no more than 2 weeks’ stock at a time and re-order regularly to reduce local wastage through expiry before use.

LAIV ordering information for school-age providers

LAIV ordering information for school-age providers School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11.55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering day.

Order day (before 11.55am cut off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders.

Please note that this does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week is in place for school provider accounts. Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk and providing your ImmForm account number or Org code.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc) will be available to order, in a single dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to less than 18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

• for GPs, there will be an initial cap of 10 doses/packs per week
• for school-age providers, there will be a cap of 450 doses/packs per week

Influenza vaccines for the 2025 to 2026 season

Information on all influenza vaccines that will be marketed in the UK for the 2025 to 2026 season are available on the flu vaccination page on GOV.UK.

Place orders only for delivery on days when your site is open

ImmForm customers should place orders only for delivery on days when their site is open and able to accept the delivery. ImmForm’s deferred order function can be used to place orders for future dates when a site is open.

Delivery failures because of a site being closed, create additional, unnecessary workload within the distribution network. In the case of a one-off closure, ImmForm customers should immediately re-schedule the delivery date of orders due for delivery on that day.

For long-term changes to the days when a site can accept deliveries, ImmForm customers should contact their Movianto Customer Care team with details. Contact details are included on each Movianto Delivery Note. Short-term changes to delivery days cannot be made, for example, for absence or holidays.

MMR vaccine ordering

M-M-RvaxPro® vaccine should be ordered for all MMR vaccinations, unless a patient requires a porcine gelatine-free MMR vaccine. ImmForm customers in England and Wales may order M-M-RvaxPro vaccine without restriction. In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix® vaccines per account per week. ImmForm customers in Scotland should refer to their local ordering restrictions. Both MMR vaccines may only be ordered for outbreak purposes when this is part of a national catch-up campaign

Non-routine vaccine supply

Hepatitis A vaccine

Adult

GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available.

Sanofi : Avaxim PFS singles are currently available. Avaxim packs of 10 are currently available.

MSD: VAQTA Adult is available.

Paediatric

GSK: supply of Havrix Paediatric singles and packs of 10 are currently available.

MSD: VAQTA Paediatric is available.

Sanofi Pasteur: Avaxim Junior singles are currently available.

Hepatitis B vaccine

Adult

GSK: Engerix B PFS singles and packs of 10 are currently available.

GSK: supply of Fendrix is currently available.

MSD: HBVAXPRO 10μg is available.

MSD: HBVAXPRO 40μg is available.

Valneva: PreHevbri is no longer marketed in the UK.

Paediatric

GSK: supplies of Engerix B Paediatric singles are currently available.

MSD: HBVAXPRO 5μg is available.

Combined hepatitis A and B vaccine

GSK: Twinrix Adult singles and packs of 10 are available.

GSK: Twinrix Paediatric is currently available.

GSK: Ambirix is available.

Combined hepatitis A and typhoid vaccine

Sanofi: Viatim is now a discontinued product and no longer available for sale.

Typhoid vaccine

Bavarian Nordic: Vivotif is available.

Sanofi: Typhim singles and packs of 10 are available.

Rabies vaccine

Bavarian Nordic: Rabipur is currently available.

Sanofi: Verorab is available to order with some restrictions – 100 doses per month per depot for wholesalers but kept 50 doses per customer per month for all other customers

Pneumococcal polysaccharide vaccine (PPV)

MSD: Private supply of Pneumovax 23 (PPV23) PFS discontinued from October 2025

Pneumococcal polysaccharide conjugate vaccine (PCV)

Pfizer: Prevenar 13 is currently available.

Pfizer: Prevenar 20 is currently available.

MSD: Vaxneuvance is currently available.

Varicella zoster vaccine

GSK: VARILRIX is currently available.

MSD: VARIVAX is available.

MSD: ZOSTAVAX is a discontinued product.

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine

Sanofi: Revaxis is available.

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

GSK: supply of Boostrix-IPV is currently available.

Sanofi: Repevax is currently available.

MMR vaccine

MSD: MMR VaxPro is currently available.

GSK: Priorix is currently available.

Meningitis ACWY vaccine

GSK: Menveo is currently available.

Pfizer: Nimenrix is currently available.

Sanofi: MenQuadfi is available.

Yellow fever vaccine

Sanofi: Stamaril is available to order without restrictions

Human papillomavirus vaccine

MSD: GARDASIL has been discontinued.

MSD: Gardasil 9 is currently available.

GSK: Cervarix has been discontinued.

Cholera vaccine

Bavarian Nordic: Vaxchora is available.

Valneva: Dukoral is available.

Japanese encephalytis vaccine

Valneva: Ixiaro is available.

Meningococcal group B vaccine

GSK: Bexsero is currently available.

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available.

Hib + meningococcal group C combined vaccine

GSK: Menitorix is currently available.

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available.

Herpes zoster vaccine

GSK: Shingrix is currently available.

Diphtheria, tetanus and pertussis

Sanofi: Adacel is currently available

Dengue tetravalent vaccine

Takeda: Qdenga is currently available.

Respiratory syncytial virus vaccine

Pfizer: Abrysvo is currently available.

GSK: Arevxy is currently available.

Chikungunya vaccine

Valneva: IXCHIQ®▼ is available. Please read important MHRA Drug Safety update on IXCHIQ® powder and solvent for solution for injection Chikungunya vaccine (live).

Bavarian Nordic: Vimkunya®▼ is available

1. RSV vaccinations by cohort ↩

2. Expansion of Shingrix® vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over letter ↩

3. National flu and COVID-19 surveillance report: 18 December 2025 (week 51) ↩